MDxHealthMDXH -6.12%45 Gross Margin % is 60.67% as of Mar. 2026, which is 1% above its 10-year median of 60.16. GuruFocus rates MDXH with a GF Score™ of 45/100 and a GF Value™ of $2.20 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, MDxHealth ranks better than 67.53% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. MDxHealth's Gross Profit for the
three
months ended in Mar. 2026 was $16.6 Mil. MDxHealth's Revenue for the
three
months ended in Mar. 2026 was $27.4 Mil. Therefore, MDxHealth's Gross Margin % for the quarter that ended in Mar. 2026 was 60.67%.
The historical rank and industry rank for MDxHealth's Gross Margin % or its related term are showing as below:
MDXH'
s Gross Margin % Range Over the Past 10 Years
Min: 0.25 Med: 60.16 Max: 74.81
Current: 63.75
During the past 13 years, the highestGross Margin % of MDxHealth was 74.81%. The lowest was 0.25%. And the median was 60.16%.
MDXH's Gross Margin % is ranked better than 67.53% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 50.45
vs MDXH: 63.75
MDxHealth had a gross margin of 60.67% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for MDxHealth was 8.70% per year.
MDxHealth (NAS:MDXH) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
MDxHealth had a gross margin of 60.67% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
MDxHealth Gross Margin % Related Terms
MDxHealth Gross Margin % Historical Data
* Premium members only.
The historical data trend for MDxHealth's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDXH vs PRPO, BIOQ, IDXG: Gross Margin % Comparison
For the Diagnostics & Research subindustry, MDxHealth's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MDxHealth Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, MDxHealth's Gross Margin % distribution charts can be found below:
* The bar in red indicates where MDxHealth's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
MDxHealth (MDXH) has a Gross Margin % of 60.67% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on MDxHealth and its competitors. This is near median its historical median of 60.16. Over the past decade, MDxHealth's Gross Margin % has ranged from 0.25 to 74.81. According to the industry distribution chart, MDxHealth ranks #63 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 32.5%.
Is MDxHealth's Gross Margin % too high?
MDxHealth's current Gross Margin % of 60.67% is near median its 10-year median of 60.16. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 74.81. The Medical Diagnostics & Research industry median Gross Margin % is 50.45. MDxHealth's value of 60.67% is 20.3% above this industry median. Based on the distribution chart, MDxHealth ranks #63 out of 194 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, MDxHealth has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MDxHealth's Gross Margin % compare to PRPO and BIOQ?
According to the Medical Diagnostics & Research industry distribution chart, MDxHealth ranks #63 out of 194 companies for Gross Margin %. This puts MDxHealth in the upper half of its industry. The industry median Gross Margin % is 50.45. MDxHealth's value of 60.67% is 20.3% above this benchmark. Historically, MDxHealth's own Gross Margin % has ranged from 0.25 to 74.81 over the past decade. While the company's 10-year median is 60.16 vs. the industry median of 50.45, MDxHealth has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 50.45, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MDxHealth's current Gross Margin % of 60.67% is 20.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on MDxHealth and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 50.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MDxHealth's current Gross Margin % is 60.67%, which is near median its own 10-year median of 60.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MDxHealth stock overvalued right now?
Based on GuruFocus' analysis, MDxHealth (MDXH) is currently considered Possible Value Trap. The stock's GF Value™ is $2.20, compared to a current price of $0.44 — trading 79.8% below its estimated fair value. The current Gross Margin % is 60.67%, which is near median its 10-year median of 60.16 and 20.3% above the Medical Diagnostics & Research industry median of 50.45. MDxHealth's overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For MDxHealth (MDXH), the current Gross Margin % is 60.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MDxHealth (MDXH) Overvalued in 2026?
Based on GuruFocus' analysis, MDxHealth stock appears to be undervalued.
The current stock price of $0.44 is trading 79.8% below its estimated GF Value™ of $2.20.
GuruFocus considers MDxHealth to be Possible Value Trap.
Key valuation signals for MDXH:
Gross Margin %: 60.67% (near median its 10-year median of 60.16)
GF Value™: $2.20 vs. price of $0.44 (79.8% below fair value)
Industry Position: 20.3% above the Medical Diagnostics & Research median (#63 of 194)
No single metric tells the full story. See the MDXH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
45GF Score
Get the complete analysis for MDXH
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDXH has been successfully added to your 
